scholarly journals Functional status is well maintained in older women during adjuvant chemotherapy for breast cancer

2003 ◽  
Vol 14 (12) ◽  
pp. 1744-1750 ◽  
Author(s):  
J.M. Watters ◽  
J.C. Yau ◽  
K. O’Rourke ◽  
E. Tomiak ◽  
S.Z. Gertler
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Functional Status ◽  
Older Women

scholarly journals Comorbidity, Chemotherapy Toxicity, and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 and CALGB 361004 (Alliance)

2014 ◽  
Vol 10 (5) ◽  
pp. e285-e292 ◽  
Author(s):  
Heidi D. Klepin ◽  
Brandelyn N. Pitcher ◽  
Karla V. Ballman ◽  
Alice B. Kornblith ◽  
Arti Hurria ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Overall Survival ◽  
Adjuvant Chemotherapy ◽  
Functional Status ◽  
Older Women ◽  
Chemotherapy Toxicity

Comorbidity was associated with shorter overall survival but not toxicity or relapse among older women with breast cancer with good functional status.

Self-Reported and Performance-Based Evaluations of Functional Status in Older Women With Breast Cancer

2021 ◽  
Vol 48 (6) ◽  
pp. 657-668
Author(s):  
Janine Overcash ◽  
Hannah Riffle ◽  
Loraine Sinnott ◽  
Nicole Williams
Keyword(s):  
Breast Cancer ◽  
Functional Status ◽  
Older Women ◽  
And Performance

Acute myeloid leukemia (AML) in older women after adjuvant breast cancer therapy

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 560-560 ◽  
Author(s):  
D. A. Patt ◽  
Z. Duan ◽  
G. Hortobagyi ◽  
S. H. Giordano
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Older Women ◽  
Proportional Hazards ◽  
Cox Proportional Hazards ◽  
Significant Independent Predictor ◽  
Kaplan Meier ◽  
Cox Proportional Hazards Models ◽  
Adjuvant Breast Cancer ◽  
Comorbidity Scores

560 Background: Adjuvant chemotherapy for breast cancer is associated with the development of secondary AML, but this risk in an older population has not been previously quantified. Methods: We queried data from the Surveillance, Epidemiology, and End Results-Medicare (SEER-Medicare) database for women who were diagnosed with nonmetastatic breast cancer from 1992–1999. We compared the risk of AML in patients with and without adjuvant chemotherapy (C), and by differing C regimens. The primary endpoint was a claim with an inpatient or outpatient diagnosis of AML (ICD-09 codes 205–208). Risk of AML was estimated using the method of Kaplan-Meier. Cox proportional hazards models were used to determine factors independently associated with AML. Results: 36,904 patients were included in this observational study, 4,572 who had received adjuvant C and 32,332 who had not. The median patient age was 75.3 (66.0–103.3). The median follow up was 63 months (13–132). Patients who received C were significantly younger, had more advanced stage disease, and had lower comorbidity scores (p<0.001). The unadjusted risk of developing AML at 10 years after any adjuvant C for breast cancer was 1.6% versus 1.1% for women who had not received C. The adjusted HR for AML with adjuvant C was 1.72 (1.16–2.54) compared to women who did not receive C. HR for radiation was 1.21 (0.86–1.70). HR was higher with increasing age but p>0.05. An analysis was performed among women who received C. When compared to other C regimens, anthracycline-based therapy (A) conveyed a significantly higher hazard for AML HR 2.17 (1.08–4.38), while patients who received A plus taxanes (T) did not have a significant increase in risk HR1.29 (0.44–3.82) nor did patients who received T with some other C HR 1.50 (0.34–6.67). Another significant independent predictor of AML included GCSF use HR 2.21 (1.14–4.25). In addition, increasing A dose was associated with higher risk of AML (p<0.05). Conclusions: There is a small but real increase in AML after adjuvant chemotherapy for breast cancer in older women. The risk appears to be highest from A-based regimens, most of which also contained cyclophosphamide, and may be dose-dependent. T do not appear to increase risk. The role of GCSF should be further explored. No significant financial relationships to disclose.

Breast Cancer Treatment Guidelines in Older Women

2005 ◽  
Vol 23 (4) ◽  
pp. 783-791 ◽  
Author(s):  
Sharon H. Giordano ◽  
Gabriel N. Hortobagyi ◽  
Shu-Wan C. Kau ◽  
Richard L. Theriault ◽  
Melissa L. Bondy
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Adjuvant Chemotherapy ◽  
Older Women ◽  
Surgical Therapy ◽  
Hormonal Therapy ◽  
Treatment Guidelines ◽  
Clinical Stage ◽  
Adjuvant Hormonal Therapy ◽  
Comorbidity Score

Purpose To determine patterns and predictors of concordance with institutional treatment guidelines among older women with breast cancer. Methods The study population included 1,568 patients aged 55 years and older who were treated at M.D. Anderson Cancer Center between July 1997 and January 2002 for stage I to IIIA invasive ductal and lobular breast cancer. Concordance with institutional guidelines was determined for definitive surgical therapy, radiotherapy after breast-conserving surgery, radiation therapy after mastectomy, adjuvant chemotherapy use, and adjuvant hormonal therapy use. The following variables were considered as possible modifiers of concordance: patient age, marital status, race, educational level, Eastern Cooperative Oncology Group performance status, comorbidity score, clinical stage, hormone receptor status, HER2-neu status, tumor grade, pathologic tumor size, lymphatic invasion, and number of lymph nodes involved. Logistic regression modeling was performed to determine the independent effect of each variable on guideline concordance. Results Older women were less likely to receive treatment in concordance with guidelines for definitive surgical therapy (P < .001), postlumpectomy radiation (P = .03), adjuvant chemotherapy (P < .001), and adjuvant hormonal therapy (P < .001). In multivariate analysis, age ≥ 75 years predicted a deviation from guidelines for definitive surgical therapy, adjuvant chemotherapy, and adjuvant hormonal therapy. Nonwhite race was associated with decreased likelihood of adjuvant radiation therapy after breast conservation. Conclusion After adjustment for comorbidity score, race, marital status, educational status, clinical stage, and tumor characteristics, increasing patient age was independently associated with decreased guideline concordance for definitive surgery, adjuvant chemotherapy, and adjuvant hormonal therapy. Future research should focus on delineating the possible reasons for guideline discordance.

scholarly journals Adjuvant Chemotherapy for Breast Cancer in Older Women

2009 ◽  
Vol 5 (5) ◽  
pp. 453-457
Author(s):  
Donald A Berry
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Older Women

scholarly journals Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial

2015 ◽  
Vol 26 (4) ◽  
pp. 675-682 ◽  
Author(s):  
F. Perrone ◽  
F. Nuzzo ◽  
F. Di Rella ◽  
A. Gravina ◽  
G. Iodice ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Older Women ◽  
Early Breast Cancer ◽  
Phase Iii ◽  
Weekly Docetaxel

Relationship of pathological features and a 21 gene expression assay in young women with early breast cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12050-e12050
Author(s):  
Martin Boniface Gitobu Mutonga ◽  
Sedona Speedy ◽  
Regina Uthe ◽  
Kelly Kindy ◽  
Aisha Brownlee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Adjuvant Chemotherapy ◽  
Older Women ◽  
Older Patients ◽  
Recurrence Score ◽  
Pathological Feature ◽  
Pathological Features ◽  
Gene Expression Assay ◽  
Gene Assay

e12050 Background: There is emerging evidence that a 21 gene expression assay recurrence score (RS) is prognostic independent of age. In practice, pathological markers may influence decision to recommend adjuvant chemotherapy. Methods: The primary objective of this study is to investigate the relationship between the RS and pathological markers between younger (29-49) and older (50-79) women with early stage ER+ breast cancer. Pathological markers investigated included the progesterone receptor (PR), grade, Ki-67, and P53. Patients who underwent 21 gene assay testing between 2002 through 2012 were sequantially identified. Data was extracted via the institutional tumor registry or chart reviewing. For each pathological feature, mean RS was compared between younger and older patients by t-tests. Trends in chemotherapy recommendation were assessed between younger and older patients within each RS risk category (≤10, 11-25, ≥26). Results: Between 2002 and 2012, 344 eligible patients were identified. 133 were ≤49 years of age, and 211 ≥50. There was no difference in distribution of RS across age (R2=3x10-4). Between younger and older patients, there was no difference in mean RS for any pathological marker (table 1). Within each age group, mean RS was always higher in tumors that were PR negative, grade 2/3, Ki67 >10%, and P53 ≥10% (p<0.05, respectively). In patients with a RS ≤10, 0% were recommended adjuvant chemotherapy irrespective of age. In patients with a RS 11-25, 39% of younger and 40% of older women were recommended chemotherapy. In patients with a RS ≥26, 100% of younger and 98% of older women were recommended chemotherapy. Conclusions: The relationships between pathological features and RS are consistent across age, supporting observations that the RS can predict benefit irrespective of age. See table. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document